The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Ginkgo Bioworks Holdings Inc (DNA) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.01, or -0.66%, to $1.51. The Ginkgo Bioworks Holdings Inc has recorded 141,708 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed XWELL, Inc. Reports Third Quarter 2023 Results.
Ginkgo Bioworks Holdings Inc is listed on the NYSE as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $1.52 and fluctuated between $1.5200 as its day high and $1.4300 as its day low. The current market capitalization of Ginkgo Bioworks Holdings Inc is $2.97B. A total of 12.22 million shares were traded on the day, compared to an average of 19.92M shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, DNA has seen 6 BUY and 45 SELL insider trades, representing the acquisition of 170,088 and the disposition of 2,446,852 shares. Over the last 12 months, there were 45 BUYs and 370 SELLs from insiders. Insiders purchased 1,707,085 shares during that period but sold 33,821,112.
In the most recent transaction, Kelly Jason R sold 100,000 shares of DNA for 1.45 per share on Nov 16. After the transaction, the insider now owns 5,094,680 company shares. In a previous transaction on Nov 16, Canton Barry sold 37,650 shares at 1.45 per share. DNA shares that 10% Owner owns now total 12,562,794.
Among the insiders who sold shares, Shetty Reshma P. disposed of 37,650 shares on Nov 16 at a per-share price of $1.45. This resulted in the insider holding 12,562,794 shares of DNA after the transaction. In another insider transaction, Kelly Jason R sold 100,000 shares at $1.54 per share on Nov 15. Company shares held by the insider now total 5,194,680.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for DNA in the last 3 months, the mean price target is $3.38 with high estimates of $7.00 and low estimates of $1.25. In terms of 52-week highs and lows, DNA has a high of $2.55 and a low of $1.12.
As of this writing, DNA has an earnings estimate of -$0.1 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.06 per share and a lower estimate of -$0.14. The company reported an EPS of -$0.09 in the last quarter, which was -12.50% lower than expectations of -$0.08.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. DNA’s latest balance sheet shows that the firm has $1.55B in Cash & Short Term Investments as of fiscal 2021. There were $23.03M in debt and $134.76M in liabilities at the time. Its Book Value Per Share was $0.68, while its Total Shareholder’s Equity was $1.57B.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DNA is Buy with a score of 3.33.